Crossmark

Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies

Crossref DOI link: https://doi.org/10.1007/s10549-021-06423-0

Published Online: 2021-10-30

Published Print: 2022-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Torres, Evanthia T. Roussos

Emens, Leisha A. https://orcid.org/0000-0002-7694-0731
License Information

Text and Data Mining valid from 2021-10-30

Version of Record valid from 2021-10-30
More Information

Article History

Received: 12 April 2021

Accepted: 12 October 2021

First Online: 30 October 2021

Declarations

:

: ERT declares no conflicts of interest. LAE discloses the following: Employment: University of Pittsburgh, UPMC UPP; Royalties: Elsevier; Intellectual Property Rights: Aduro Biotech; Consulting fees; Genentech, F Hoffman La Roche, Syndax, Lilly, Abbvie, Astrazeneca, Medimmune, Bayer, GCPR, Gilead, Gritstone, Macrogenics, Novartis, Peregrine, Replimune, Shionogi, Silverback, Vaccinex, Celgene, Chugai; Travel support: Genentech, F Hoffman La Roche, Amgen, Macrogenics, Replimune, Vaccinex, Bristol Myers Squibb; Contracted research: Abbvie, Aduro Biotech, Astrazeneca, Bolt Therapeutics, Bristol Myers Squibb, Corvus, EMD Serono, Genentech, F Hoffman La Roche, Maxcyte, Merck, Silverback, Tempest, Takeda, CytomX, Compugen; Third party publication support: Genentech/F Hoffman La Roche; In kind support (provision of drug for preclinical studies). The author is the current Vice President for the Society for the Immunotherapy of Cancer (2021–2022) and a former at-large member of the Board of Directors from 2016 to 2019.

Document is current

Any future updates will be listed below